ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]), according to a study published online May 30 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Elena Elez, M.D., Ph.D., from Vall d'Hebron Hospital Campus in Barcelona, Spain and colleagues conducted an open-label study in which they randomly assigned patients with untreated BRAF V600E-mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care consisting of chemotherapy with or without bevacizumab (158, 236, and 243 patients, respectively). Data on progression-free survival and an updated interim analysis of overall survival were presented.

The researchers found that progression-free survival was significantly longer with EC+mFOLFOX6 than standard care (median, 12.8 versus 7.1 months; hazard ratio for progression or death, 0.53). Overall survival was significantly longer with EC+mFOLFOX6 than with standard care in an interim analysis (median, 30.3 versus 15.1 months; hazard ratio for death, 0.49). The incidence of serious adverse events during treatment was 46.1 and 38.9 percent with EC+mFOLFOX6 and standard care, respectively; safety profiles were consistent with known profiles for each agent.

"The benefits with regard to both progression-free survival and overall survival with EC+mFOLFOX6 were observed across all the prespecified clinical subgroups, including in patients with liver metastases or with involvement of three or more organs," the authors write.

Several authors disclosed ties to Pfizer, which funded the study, with support from Ono Pharmaceutical, Merck, and Eli Lilly.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords